Medtronic (NYSE:MDT) Sees Unusually-High Trading Volume – What’s Next?

Posted by Brenda Bartman on Oct 6th, 2026

Shares of Medtronic PLC (NYSE:MDT – Get Free Report) saw an uptick in trading volume on Tuesday. 32,780,431 shares changed hands during trading, an increase of 238% from the previous session’s volume of 9,703,300 shares. The stock last traded at $86.5610 and had previously closed at $87.97.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MDT. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Wells Fargo & Company raised their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Finally, Truist Financial reissued a “hold” rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Nineteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.92.

Check Out Our Latest Stock Analysis on MDT

Medtronic Stock Down 1.7%

The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $110.67 billion, a price-to-earnings ratio of 21.32, a PEG ratio of 1.97 and a beta of 0.55. The stock has a fifty day moving average of $90.22 and a 200-day moving average of $84.76.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

A number of institutional investors have recently bought and sold shares of MDT. Rosenberg Matthew Hamilton increased its stake in Medtronic by 65.9% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 695 shares of the medical technology company’s stock valued at $60,000 after buying an additional 276 shares during the period. Adelphi Trust Co boosted its stake in shares of Medtronic by 5.6% during the 3rd quarter. Adelphi Trust Co now owns 3,245 shares of the medical technology company’s stock valued at $280,000 after buying an additional 173 shares during the period. Eastern Bank grew its holdings in shares of Medtronic by 2.9% during the 3rd quarter. Eastern Bank now owns 21,610 shares of the medical technology company’s stock valued at $1,865,000 after acquiring an additional 613 shares in the last quarter. Rockland Trust Co. boosted its position in Medtronic by 10.2% during the third quarter. Rockland Trust Co. now owns 10,113 shares of the medical technology company’s stock valued at $873,000 after purchasing an additional 936 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Medtronic by 14.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company’s stock valued at $12,918,000 after purchasing an additional 19,315 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.